Program
mRNA-1010 influenza vaccine
Also written as “mRNA-1010”, “mRNA-1010.4” and “mRNA-1010.6”.
Its studies are mostly in Influenza, Human · Coronavirus Infections, led by Moderna.
Furthest: phase 4, since Oct 13, 202612 company-led studies, 2 open or runningNext primary completion: Dec 7, 2026 (phase 4)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Moderna | 122 open or running | phase 4since Oct 13, 2026 | Jun 30, 2021 | Dec 7, 2026phase 4 · NCT07884175 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 30, 2021First study: phase 2 study in Influenza, HumanFirst studyNCT04956575 · 885 enrolled · United States
- May 13, 2022Phase 2 study in Influenza, HumanNCT05375838 · 550 enrolled · United States
- May 25, 2022Phase 1 study in Coronavirus InfectionsNCT05397223 · 308 enrolled · United States
- Jun 8, 2022Phase 3 study in Seasonal InfluenzaNCT05415462 · 6,102 enrolled · Argentina, Australia, Colombia and more
- Sep 30, 2022Phase 3 study in Influenza, HumanNCT05566639 · 22,502 enrolled · United States, Bulgaria, Canada and more
- Oct 14, 2022Phase 1 study in Influenza, HumanNCT05585632 · 392 enrolled · United States, Australia, United Kingdom
- Oct 31, 2022Phase 2 study in Influenza, HumanNCT05606965 · 172 enrolled · United States
- Apr 13, 2023Phase 3 study in Virus DiseasesNCT05827978 · 8,411 enrolled · United States
- May 11, 2023Phase 2 study in Influenza, HumanNCT05868382 · 270 enrolled · United States
- Sep 15, 2024Phase 3 study in Influenza, HumanNCT06602024 · 40,805 enrolled · United States, Belgium, Bulgaria and more
- Oct 6, 2026Phase 1 study in Influenza, HumanNCT07870330 · 96 planned · United States
- Oct 13, 2026Phase 4 study in Influenza, HumanNCT07884175 · 200 planned · United States
Ahead
- Dec 7, 2026Primary completion: phase 4 study in Influenza, HumanNCT07884175
- Dec 7, 2027Primary completion: phase 1 study in Influenza, HumanNCT07870330
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07884175Influenza, Human · United States | 4 | Recruiting | Dec 7, 2026 | 200 |
| NCT07870330Influenza, Human · United States | 1 | Recruiting | Dec 7, 2027 | 96 |
| NCT06602024Influenza, Human · United States, Belgium, Bulgaria and more | 3 | Completed | Aug 21, 2025 | 40,805 |
| NCT05868382Influenza, Human · United States | 2 | Completed | Dec 19, 2023 | 270 |
| NCT05827978Virus Diseases · United States | 3 | Completed | Jun 24, 2024 | 8,411 |
| NCT05606965Influenza, Human · United States | 2 | Completed | Nov 13, 2025 | 172 |
| NCT05585632Influenza, Human · United States, Australia, United Kingdom | 1 | Completed | Feb 28, 2024 | 392 |
| NCT05566639Influenza, Human · United States, Bulgaria, Canada and more | 3 | Completed | Jan 5, 2024 | 22,502 |
| NCT05415462Seasonal Influenza · Argentina, Australia, Colombia and more | 3 | Completed | Sep 4, 2023 | 6,102 |
| NCT05397223Coronavirus Infections · United States | 1 | Completed | Feb 27, 2026 | 308 |
| NCT05375838Influenza, Human · United States | 2 | Completed | Dec 29, 2022 | 550 |
| NCT04956575Influenza, Human · United States | 2 | Completed | Sep 27, 2022 | 885 |
How it is read
Names in the registry
- “mRNA-1010”, 12 entries
- “mRNA-1010.4”, 1 entry
- “mRNA-1010.6”, 1 entry
Codes read as this program: MRNA1010.
Conditions, from the studies’ own filings
- Influenza, Human, 11 studies
- Coronavirus Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.